Showing 1991-2000 of 2150 results for "".
- Thomas Burns, CEO of Glaukos, Joins Avedro’s Board of Directorshttps://modernod.com/news/thomas-burns-ceo-of-glaukos-joins-avedros-board-of-directors/2479974/Avedro announced that Thomas W. Burns has been elected to its board of directors. Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a mem
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Novartis Announces Intention to Spinoff Alcon Into Standalone Companyhttps://modernod.com/news/novartis-announces-intention-to-spinoff-alcon-and-launch-a-5-billion-share-buyback/2480055/After months of speculation, Novartis confirmed on Friday its intention to spinoff Alcon into a separately-traded standalone company. The major transaction would enable Novartis to focus on bringing new drugs to market, while allowing Alcon to focus on its core offerings in the surgical and visio
- Ultrasonic Phaco Remains Dominant, but New Technologies Ready to Challengehttps://modernod.com/news/ultrasonic-phaco-remains-dominant-but-new-technologies-ready-to-challenge/2480114/Market Scope expects surgeons to perform nearly 18.5 million phaco procedures globally in 2018, and dedicated packs and accessories will make up more than 72 percent of the $1.6 billion in global cataract equipment revenues. Two factors will fuel modest growth in the cataract equipment mar
- Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-presentation-of-new-data-on-lo2a-in-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome/2480143/Wize Pharma announced recently reported new data on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute. The poster presentation presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
- President Trump Outlines Plan to Lower Drug Costshttps://modernod.com/news/president-trump-outlines-plan-to-lower-drug-costs/2480151/President Donald Trump on Friday unveiled plans to increase competition in the prescription medicine market and lower patients’ out-of-pocket costs in an effort to tackle high drug prices in the US. Under the plan, dubbed American Patients First, rules preventing government programmes from
- Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care for Primary Care Facilitieshttps://modernod.com/news/siemens-healthineers-and-hill-rom-to-provide-comprehensive-diabetes-care-for-primary-care-facilities/2480156/Siemens Healthineers and Hill-Rom signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that, for the first time, enable primary healthcare providers in the United States to bridge gaps in diabetes care and satisfy value-based quality measures in a single offi
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eyehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome-in-a-mouse-model-at-arvo/2480176/ReGenTree announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at the ARVO meeting. The study was conducted by Jaewook Yan
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndromehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome/2480185/ReGenTree, a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology)